Recently, according to media reports, the State Drug Administration has approved Xiamen Wantai Bohai Biotechnology Co., Ltd. bivalent human papillomavirus vaccine (E. coli) (commodity name: Cecolin) listing registration application, the drug is the first approved domestic human papillomavirus (HPV) vaccine, Suitable for women aged 9-45.
Reported that the vaccine for The Wantai company and Xiamen University jointly developed and translated by Wantai, China’s independent research and development of the first independent research and development of cervical cancer vaccine, which will become the world’s third, China’s first approved HPV vaccine, meaning that China’s cervical cancer vaccine will end the history of dependence on imports.
The human papillomavirus (HPV) vaccine, commonly known as the cervical cancer vaccine, can be used to prevent cervical cancer in women and male and female genital cancer, as well as genital warts. There are currently three hpv vaccines on the market worldly, namely, the gupalosic vaccine for HPV16 and 18 produced by GlaxoSmithKline in the United Kingdom, the quadrined vaccine for HPV6, 11, 16, 18 and the vaccine against HPV6, 11, 16, 18, 31, 33, 45, 52, Type 58 nine-price vaccine.
According to statistics, HPV is the fourth most common cancer in women, with about 570,000 new cases of cervical cancer and about 311,000 deaths worldwide in 2018.
The approved bivalent human papillomavirus vaccine (E. coli) for HPV16, 18 type, included in the national major new drug creation special support. When approved for listing, it will further meet public demand and improve product accessibility.